Humacyte Q2 FY26 earnings call HUMA

Humacyte announced breakthrough top-line interim results from its V012 Phase 3 trial in female dialysis patients, demonstrating that its acellular tissue engineered vessel (ATEV) significantly outperformed autologous fistula, the current standard of care. Patients receiving ATEV achieved 91 more catheter-free days than those with AV fistula, a highly statistically significant difference (p=0.0007). Furthermore, ATEV showed a lower infection rate of 6 per 100 patient-years compared to 23 for AV fistula, representing a major advance for hemodialysis, particularly for women who have historically faced challenges with fistula procedures.

Following the positive V012 trial results, Humacyte plans to submit a Supplemental Biologics License Application (sBLA) to the FDA in November, targeting priority review due to its RMAT designation and existing approval. This could lead to a PDUFA date in May 2027 and a potential launch by the end of Q2 2027. The company is heavily focused on health economics and reimbursement strategies, emphasizing the significant cost savings (estimated $20,000-$40,000 per patient annually) from reducing reliance on infection-prone catheters, which are expensive for the healthcare system.

The FDA accepted Humacyte's Investigational New Drug (IND) application for a first-in-human Phase 2a clinical study of its coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG). CTEV, a smaller-diameter version of ATEV, has undergone over 5 years of preclinical testing in large animals. This marks a significant milestone as it represents the first new off-the-shelf conduit to be prospectively tested in CABG in the U.S. in over 40 years, with the Phase 2a study of 10 patients expected to commence in Q3 FY26.

Humacyte has undertaken a significant commercial rebuild for Symbest in the vascular injury indication, focusing on driving product adoption and utilization. Key initiatives include remodeling the commercial team with individuals possessing deep vascular surgery relationships, refining introductory pricing incentives, enhancing professional education, and streamlining Value Analysis Committee (VAC) engagement. This new strategy is beginning to show results, with 20 major healthcare systems currently in the process of adopting Symbest in the second half of 2026, laying the groundwork for sustained revenue growth.

To bolster its commercial and scientific efforts, Humacyte made several strategic appointments. Jim Mercadante was appointed Chief Commercial Officer in April, bringing extensive experience in medical devices and healthcare technology. Dr. Todd Rasmussen, with a 28-year military career in vascular surgery, joined as Chief Surgical Officer. Additionally, Dr. Robert Kossman and Dr. Prabir Roy-Chaudhury were appointed as advisors for the dialysis access commercialization, providing expertise in health economics, reimbursement, and market access strategies.

Beyond U.S. efforts, Humacyte's Marketing Authorization Application for Symbest for arterial injury repair was accepted for review by the Israel Ministry of Health in April 2026, with a 180-day working period. The company is also actively engaging with the U.S. Department of Defense and Pentagon leaders to ensure appropriate access to Symbest for American service personnel suffering traumatic vascular injuries, following dedicated funding included in the fiscal 2026 Appropriations Act.